$0.24
+0.01 (+2.17%)
Open$0.24
Previous Close$0.23
Day High$0.24
Day Low$0.23
52W High$0.86
52W Low$0.16
Volume—
Avg Volume517.9K
Market Cap10.57M
P/E Ratio—
EPS$-2.50
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+16,380.9% upside
Current
$0.24
$0.24
Target
$38.73
$38.73
$26.34
$38.73 avg
$46.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.08M | 955.9K |
| Net Income | -22,361 | -31,787 | -25,174 |
| Profit Margin | -2.2% | -2.9% | -2.6% |
| EBITDA | -38,355 | -35,389 | -33,870 |
| Free Cash Flow | -18,843 | -19,077 | -22,857 |
| Rev Growth | +0.6% | -3.8% | +4.7% |
| Debt/Equity | 0.84 | 0.93 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |